In this episode, we sit down with Caitlyn Krebs, Co-founder and CEO of Nalu Bio, to discuss how her company is leveraging generative AI to revolutionize drug discovery. Caitlyn shares how they are creating novel chemical entities five times faster than traditional methods to tackle massive unmet needs like endometriosis and post-surgical pain.

We also dive deep into the business of biotech: the looming $250 billion "Patent Cliff" facing big pharma, the reality of the fundraising "rollercoaster," and why bringing innovation back to the US is critical for the industry's future.

If you are interested in the intersection of AI and biology, the future of pain management, or the grit required to build a life sciences startup, you won't want to miss this conversation.

⭐ Sponsored by Podcast10x - Podcasting agency for VCs - https://podcast10x.com

Key Topics Covered:

- The Next GLP-1? Why the endocannabinoid system is the largest regulator in the human body.

- AI in Biotech: How Nalu Bio uses "digital twins" and virtual patients to de-risk drug development.

- The $250B Opportunity: Understanding the massive patent cliff approaching the pharma industry.

- Women's Health: Solving endometriosis with non-hormonal, non-opioid therapeutics.

- Founder Resilience: Caitlyn’s story of a lead investor walking away at the final document stage and how she bounced back.

- Building Moats: How to protect IP and technology in a competitive market.

Connect with Caitlyn & Nalu Bio:

* Website: https://nalubio.com

* LinkedIn: https://www.linkedin.com/in/caitlynkrebs

* Email: caitlyn@nalubio.com

VC10X website - https://VC10X.com

Don't forget to LIKE, SUBSCRIBE, and turn on notifications for more deep dives into the future of technology and healthcare!

#Biotech #AI #DrugDiscovery #Endometriosis #Startup #NaluBio #HealthTech #Entrepreneurship #GLP1 #Pharma

Founder10x - The $250B Patent Cliff: How AI is Reshaping Drug Discovery

VC10X - Investing, Venture Capital, Asset Management, Private Equity, Family Office